February 2, 2012
The Editor-in-Chief has granted immediate free access to the articles below:
-
Hematopoietic stem cell engineering at a crossroads
-
High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement
-
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase
3 trial (DASISION)
-
Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211–labeled anti-CD45 antibody for conditioning
in allogeneic hematopoietic cell transplantation
-
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
e-LETTERS
Most recent
ANNOUNCEMENTS
-
ASH Image Bank, Re-launched, Enhanced, and Free -
Announcing Blood 2.0 -
ASH launches Hematology Web Focus: a unique resource for clinicians -
Now available! ASH Self-Assessment Program Fourth Edition Standard (print with online access and online only) -
Blood now offers faster feedback through e-Letters -
Blood cited as one of the top 100 influential biology and medicine journals -
ASH’s alternative to NIH policy on public access
THREE MOST FREQUENTLY READ ARTICLES +more collections
